Real World Evidence Opportunities in Germany
12 May 2020, 16:00 CEST
webinar

Real world Evidence opportunities in Germany

In this webinar we will give an overview of how the different stakeholders see the use of real world evidence in evaluation, pricing, and reimbursement decisions of new drugs. A special focus will be on current developments and legislative changes that may lead to increased importance of RWE in Germany.

The webinar will also provide an overview of the type of data-sets that are available in Germany for Real World Evidence studies and describe how they can be used to generate scientific evidence and to support market access processes. Different phases of the drug development process will be covered from early epidemiology through P4P and payer contracting.

Speakers:

Dr Holger Gothe, Director, Health Services Research

Holger Gothe holds a Doctoral degree in Medicine from the Free University of Berlin, Germany, and possesses a license to practice medicine since 1988. He also holds a Diploma in “Communication in Social and Economic Contexts” from the Berlin University of Arts. He joined IGES in 2000 with a strong focus on health services and outcomes research. From 2009 to 2016, before he returned to IGES, he held the Deputy Chair position at the Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment at UMIT – University of Health Sciences, Medical Informatics and Technology in Hall i. T., Austria.

Holger’s research interests encompass the utilization of administrative data and claims data for pharmacoepidemiological and pharmacoeconomic purposes. His methodological en-deavors are dedicated to the utilization of real-world data in the analysis of health conditions and health care provision as well as access and implementation of innovation in health care systems, mainly regarding pharmacotherapy and medical devices.

Prior to joining IGES, Holger collected experience in various academic positions at public and private Universities, as well as in the pharmaceutical industry in the field of medical marketing. Holger is continuously engaged in the educational sector holding several academic appoint-ments as a University lecturer, both in and outside Germany. Besides that, he is a dedicated member of several scientific societies. He acts as a board member (Vice President) of the German Society of Pharmacoepidemiology and Drug Utilization Research (GAA), speaker of the Working Group for Acquisition and Utilization of Secondary Data (AGENS). Holger has authored more than 100 publications including scientific textbooks, book chapters, and scientific articles. He is member of the editorial board of two scientific journals and achieved several scientific awards.

Fabian Berkemeier, Director, Value & Access Strategy

Fabian Berkemeier studied economic engineering with a specialization on health technology at the Technical University of Berlin and the KTH Royal Institute of Technology (Stockholm, Sweden). He joined IGES in 2015 and his work focuses on strategic market access consulting for highly innovative therapies incorporating health outcomes, health economics, policy, and stakeholder engagement. He also has experience in strategic consulting for the preparation of dossiers for early benefit assessment as well as comprehensive knowledge of the AMNOG process.

Prior to joining IGES, Fabian collected experience in the fields of market access (top 10 pharmaceutical manufacturer) and health politics (German ministry of health). Fabian also conducts Real World Evidence research on the effects of drug regulation on healthcare utilization as part of a Ph.D. at Berlin Institute of Technology and the University of California Berkeley.